Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
By Shannon L. Stott, Chia-Hsien Hsu, D. Tsukrov, Min Yu, D. Miyamoto, B. A. Waltman, S. Rothenberg, Ajay M Shah, Malgorzata E. Smas, George K Korir and 13 more. Proceedings of the National Academy of Sciences of the United States of America, 2010
1,612 citations recorded by the source corpus.
Subfields: Biomedical Engineering, Oncology
View Paper: https://www.semanticscholar.org/paper/983c5e60ede311cfe6d3a64e1000137147ae10cc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
- D. Di Carlo
- Mehmet Toner
- C. Hansen
- Richard M. Maceiczyk
- R. Wootton
- D. Chiu
- Patrick Doyle
- Andrew deMello
In Oncology
Citations in the corpus
- Small but Perfectly Formed? Successes, Challenges, and Opportunities for Microfluidics in the Chemical and Biological Sciences (2017, background): “For example, the ability to direct streams of cells to surfaces allows trapping and concentration based on surface-specific antigens, whereas the ability to direct cells to specific streamlines on the basis of size, electrical properties, or deformability allows selective concentration based on phys”
- Circulating Tumor Cell Clusters are Oligoclonal Precursors of Breast Cancer Metastasis (2014, methodology): “…a series of microfluidic devices that have the advantage of low-shear, yet high throughput, interrogation of unprocessed whole blood, providing highly enriched and unfixed CTCs that are suitable for detailed molecular analysis (Nagrath et al., 2007; Ozkumur et al., 2013; Stott et al., 2010).”
- Tumor Metastasis: Molecular Insights and Evolving Paradigms (2011, neutral): “Recent technological advances have facilitated detection of circulating tumor cells (CTCs) within the bloodstream of carcinoma patients (Nagrath et al., 2007; Pantel et al., 2008; Stott et al., 2010).”
- Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “However, increasing the sensitivity of CTC analyses may also lead to false-positive results in healthy controls (71) or benign inflammatory diseases (65).”